← Back to Screener
OS Therapies Incorporated (OSTX)
Price$1.38
Favorite Metrics
Price vs S&P 500 (26W)-38.90%
Price vs S&P 500 (4W)-19.23%
Market Capitalization$58.43M
All Metrics
Book Value / Share (Quarterly)$0.14
Cash Flow / Share (Quarterly)$-0.40
Price vs S&P 500 (YTD)-4.85%
EPS (TTM)$-0.96
10-Day Avg Trading Volume0.77M
EPS Excl Extra (TTM)$-0.96
EPS (Annual)$-0.98
ROI (Annual)-1094.65%
Cash / Share (Quarterly)$0.01
ROA (Last FY)-420.41%
EBITD / Share (TTM)$-1.00
Cash Flow / Share (Annual)$-0.40
P/B Ratio12.41x
P/B Ratio (Quarterly)13.96x
Net Income / Employee (Annual)$-7
Net Interest Coverage (TTM)-3.33x
ROA (TTM)-378.92%
EPS Incl Extra (Annual)$-0.98
Current Ratio (Annual)0.03x
Quick Ratio (Quarterly)0.02x
3-Month Avg Trading Volume0.58M
52-Week Price Return-11.46%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.02
52-Week High$2.57
EPS Excl Extra (Annual)$-0.98
26-Week Price Return-30.15%
Quick Ratio (Annual)0.02x
13-Week Price Return-10.32%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.03x
Enterprise Value$58.163
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.01
3-Month Return Std Dev62.68%
Net Income / Employee (TTM)$-7
ROE (Last FY)-1094.65%
Net Interest Coverage (Annual)-3.33x
EPS Basic Excl Extra (Annual)$-0.98
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.96
ROI (TTM)-567.59%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-46.56%
Year-to-Date Return-0.71%
5-Day Price Return5.30%
EPS Normalized (Annual)$-0.98
ROA (5Y Avg)-1012.51%
Month-to-Date Return-1.42%
EBITD / Share (Annual)$-0.97
EPS Basic Excl Extra (TTM)$-0.96
P/TBV (Quarterly)71.95x
P/B Ratio (Annual)112.02x
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)-13.19%
Beta0.38x
Revenue / Share (TTM)$0.00
ROE (TTM)-567.59%
52-Week Low$1.15
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | — | — | — | — | $1.38 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
OS Therapies is a clinical-stage biopharmaceutical company developing treatments for osteosarcoma and other solid tumors in children and young adults. The company addresses an unmet medical need in pediatric and adolescent bone cancer therapeutics.